NewEdge Wealth LLC Buys 15,503 Shares of Johnson & Johnson (NYSE:JNJ)

NewEdge Wealth LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 8.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 203,057 shares of the company’s stock after buying an additional 15,503 shares during the quarter. NewEdge Wealth LLC’s holdings in Johnson & Johnson were worth $29,366,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Magnolia Private Wealth LLC bought a new position in Johnson & Johnson during the fourth quarter valued at about $202,000. Nelson Capital Management LLC grew its position in Johnson & Johnson by 10.9% during the fourth quarter. Nelson Capital Management LLC now owns 6,124 shares of the company’s stock valued at $886,000 after buying an additional 601 shares during the period. Shayne & Jacobs LLC boosted its position in Johnson & Johnson by 7.8% during the fourth quarter. Shayne & Jacobs LLC now owns 2,094 shares of the company’s stock worth $303,000 after purchasing an additional 152 shares during the period. National Pension Service boosted its position in Johnson & Johnson by 0.4% during the fourth quarter. National Pension Service now owns 4,586,490 shares of the company’s stock worth $663,298,000 after purchasing an additional 18,836 shares during the period. Finally, Fjell Capital LLC bought a new position in Johnson & Johnson during the fourth quarter worth about $898,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.9 %

Shares of JNJ opened at $165.23 on Friday. The firm’s 50 day simple moving average is $150.90 and its 200 day simple moving average is $156.06. The company has a market capitalization of $397.81 billion, a P/E ratio of 24.85, a P/E/G ratio of 2.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period last year, the firm posted $2.29 earnings per share. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.00%. Johnson & Johnson’s payout ratio is 74.59%.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on JNJ shares. Guggenheim increased their target price on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Stifel Nicolaus cut their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Raymond James cut their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Leerink Partners cut their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Finally, Morgan Stanley lowered their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.